S&P 500   4,286.89 (+0.31%)
DOW   33,637.53 (+0.06%)
QQQ   355.72 (+0.43%)
AAPL   172.41 (+0.26%)
MSFT   313.24 (+0.35%)
META   300.80 (+0.62%)
GOOGL   129.90 (+1.03%)
AMZN   127.09 (+0.88%)
TSLA   244.62 (+0.20%)
NVDA   425.38 (+1.50%)
NIO   8.39 (-0.24%)
BABA   86.30 (+0.45%)
AMD   97.63 (+1.74%)
T   14.91 (-0.73%)
F   12.42 (-0.08%)
MU   67.83 (-0.16%)
CGC   0.95 (+3.18%)
GE   110.64 (+0.65%)
DIS   80.23 (+0.22%)
AMC   8.06 (+1.90%)
PFE   32.30 (-0.31%)
PYPL   59.16 (+0.39%)
NFLX   382.36 (+0.82%)
S&P 500   4,286.89 (+0.31%)
DOW   33,637.53 (+0.06%)
QQQ   355.72 (+0.43%)
AAPL   172.41 (+0.26%)
MSFT   313.24 (+0.35%)
META   300.80 (+0.62%)
GOOGL   129.90 (+1.03%)
AMZN   127.09 (+0.88%)
TSLA   244.62 (+0.20%)
NVDA   425.38 (+1.50%)
NIO   8.39 (-0.24%)
BABA   86.30 (+0.45%)
AMD   97.63 (+1.74%)
T   14.91 (-0.73%)
F   12.42 (-0.08%)
MU   67.83 (-0.16%)
CGC   0.95 (+3.18%)
GE   110.64 (+0.65%)
DIS   80.23 (+0.22%)
AMC   8.06 (+1.90%)
PFE   32.30 (-0.31%)
PYPL   59.16 (+0.39%)
NFLX   382.36 (+0.82%)
S&P 500   4,286.89 (+0.31%)
DOW   33,637.53 (+0.06%)
QQQ   355.72 (+0.43%)
AAPL   172.41 (+0.26%)
MSFT   313.24 (+0.35%)
META   300.80 (+0.62%)
GOOGL   129.90 (+1.03%)
AMZN   127.09 (+0.88%)
TSLA   244.62 (+0.20%)
NVDA   425.38 (+1.50%)
NIO   8.39 (-0.24%)
BABA   86.30 (+0.45%)
AMD   97.63 (+1.74%)
T   14.91 (-0.73%)
F   12.42 (-0.08%)
MU   67.83 (-0.16%)
CGC   0.95 (+3.18%)
GE   110.64 (+0.65%)
DIS   80.23 (+0.22%)
AMC   8.06 (+1.90%)
PFE   32.30 (-0.31%)
PYPL   59.16 (+0.39%)
NFLX   382.36 (+0.82%)
S&P 500   4,286.89 (+0.31%)
DOW   33,637.53 (+0.06%)
QQQ   355.72 (+0.43%)
AAPL   172.41 (+0.26%)
MSFT   313.24 (+0.35%)
META   300.80 (+0.62%)
GOOGL   129.90 (+1.03%)
AMZN   127.09 (+0.88%)
TSLA   244.62 (+0.20%)
NVDA   425.38 (+1.50%)
NIO   8.39 (-0.24%)
BABA   86.30 (+0.45%)
AMD   97.63 (+1.74%)
T   14.91 (-0.73%)
F   12.42 (-0.08%)
MU   67.83 (-0.16%)
CGC   0.95 (+3.18%)
GE   110.64 (+0.65%)
DIS   80.23 (+0.22%)
AMC   8.06 (+1.90%)
PFE   32.30 (-0.31%)
PYPL   59.16 (+0.39%)
NFLX   382.36 (+0.82%)
NASDAQ:KDNY

Chinook Therapeutics (KDNY) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$40.29
▼
$40.51
50-Day Range
$38.66
▼
$40.39
52-Week Range
$18.34
▼
$40.51
Volume
4.92 million shs
Average Volume
1.19 million shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.14
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Chinook Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.23 Rating Score
Upside/​Downside
5.6% Downside
$38.14 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$45,587 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.30) to ($3.50) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.83 out of 5 stars

Medical Sector

954th out of 963 stocks

Biotechnology Industry

17th out of 19 stocks

See Top Rated MarketRank™ Stocks Here

KDNY stock logo

About Chinook Therapeutics (NASDAQ:KDNY) Stock

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.


KDNY Stock News Headlines

August 8, 2023 | msn.com
Wedbush Downgrades Chinook Therapeutics (KDNY)
August 2, 2023 | uk.finance.yahoo.com
Chinook Therapeutics, Inc. (KDNY)
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 1, 2023 | markets.businessinsider.com
Expert Ratings for Chinook Therapeutics
August 1, 2023 | msn.com
Wells Fargo Downgrades Chinook Therapeutics (KDNY)
July 25, 2023 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KDNY, NETI, TALS, QUOT
July 16, 2023 | fool.com
Chinook Therapeutics (NASDAQ: KDNY)
June 21, 2023 | seekingalpha.com
Chinook: Surprising Acquisition By Novartis, Deal Should Go Through
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
June 17, 2023 | finance.yahoo.com
Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress
June 16, 2023 | benzinga.com
Moore Kuehn Encourages NETI, SURF, KDNY, and NEX Investors to Contact Law Firm
June 14, 2023 | businesswire.com
CHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook ...
June 13, 2023 | barrons.com
KDNY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chinook Therapeutics, Inc. Is Fair to Shareholders
June 13, 2023 | reuters.com
Novartis buys Chinook for $3.5 bln in race to treat rare kidney disease
June 13, 2023 | markets.businessinsider.com
Why Are Chinook Therapeutics Shares Trading Higher Today
June 12, 2023 | markets.businessinsider.com
What 6 Analyst Ratings Have To Say About Chinook Therapeutics
June 12, 2023 | finance.yahoo.com
Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress
June 12, 2023 | seekingalpha.com
Novartis Buys Chinook: M&A To Drive Future Growth
June 12, 2023 | investorplace.com
Why Is Chinook Therapeutics (KDNY) Stock Up 58% Today?
June 8, 2023 | markets.businessinsider.com
Chinook Shareholder Action Reminder
May 23, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM), Chinook Therapeutics (KDNY) and Zoetis (ZTS)
May 21, 2023 | benzinga.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY
May 21, 2023 | benzinga.com
Chinook Shareholder Notice
May 19, 2023 | seekingalpha.com
Chinook Therapeutics: Travere's Pain Is Chinook's Gain
May 19, 2023 | benzinga.com
Chinook Investor Alert
May 18, 2023 | benzinga.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors
May 17, 2023 | benzinga.com
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors
See More Headlines
Receive KDNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chinook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KDNY Company Calendar

Last Earnings
8/07/2023
Today
9/27/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KDNY
CUSIP
N/A
CIK
1435049
Web
chinooktx.com
Phone
(206) 485-7241
Fax
N/A
Employees
214
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$38.14
High Stock Price Forecast
$43.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
-5.6%
Consensus Rating
Hold
Rating Score (0-4)
2.23
Research Coverage
13 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.52)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-187,870,000.00
Net Margins
-4,199.93%
Pretax Margin
-4,115.56%
Return on Equity
-58.28%
Return on Assets
-44.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.82
Quick Ratio
5.82

Sales & Book Value

Annual Sales
$6.13 million
Price / Sales
473.15
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.91 per share
Price / Book
5.85

Miscellaneous

Outstanding Shares
71,810,000
Free Float
59,749,000
Market Cap
$2.90 billion
Optionable
Optionable
Beta
0.34
A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Eric L. Dobmeier J.D. (Age 54)
    Pres, CEO & Director
    Comp: $972.19k
  • Mr. Tom FrohlichMr. Tom Frohlich (Age 47)
    Chief Operating Officer
    Comp: $627.44k
  • Mr. Andrew James King D.V.M.Mr. Andrew James King D.V.M. (Age 43)
    Ph.D., Chief Scientific Officer
    Comp: $651.48k
  • Mr. Eric H. Bjerkholt M.B.A. (Age 63)
    Chief Financial Officer
  • Ms. Sukhi Thethy
    Sr. VP of Fin. & Accounting
  • Ms. Noopur Batsha Liffick
    Sr. VP of Investor Relations & Corp. Communications
  • Mr. Kirk D. Schumacher J.D.
    Sr. VP & Gen. Counsel
  • Ms. Jodi Jamieson
    Sr. VP of HR
  • Dr. Alan Glicklich M.D. (Age 60)
    Exec. Officer
  • Ms. Delphine Imbert Ph.D.
    Sr. VP of CMC & Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













KDNY Stock - Frequently Asked Questions

Should I buy or sell Chinook Therapeutics stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last twelve months. There are currently 10 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" KDNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KDNY, but not buy additional shares or sell existing shares.
View KDNY analyst ratings or view top-rated stocks.

What is Chinook Therapeutics' stock price forecast for 2023?

13 Wall Street research analysts have issued 12 month price objectives for Chinook Therapeutics' shares. Their KDNY share price forecasts range from $32.00 to $43.00. On average, they anticipate the company's share price to reach $38.14 in the next year. This suggests that the stock has a possible downside of 5.6%.
View analysts price targets for KDNY or view top-rated stocks among Wall Street analysts.

When is Chinook Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our KDNY earnings forecast.

How were Chinook Therapeutics' earnings last quarter?

Chinook Therapeutics, Inc. (NASDAQ:KDNY) posted its quarterly earnings data on Monday, August, 7th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.81) by $0.13. The business earned $1.01 million during the quarter, compared to analysts' expectations of $0.47 million. Chinook Therapeutics had a negative trailing twelve-month return on equity of 58.28% and a negative net margin of 4,199.93%.

What ETFs hold Chinook Therapeutics' stock?

ETFs with the largest weight of Chinook Therapeutics (NASDAQ:KDNY) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), AltShares Merger Arbitrage ETF (ARB), ProShares Merger ETF (MRGR), First Trust Merger Arbitrage ETF (MARB), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Simplify Propel Opportunities ETF (SURI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What other stocks do shareholders of Chinook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR).

What is Chinook Therapeutics' stock symbol?

Chinook Therapeutics trades on the NASDAQ under the ticker symbol "KDNY."

Who are Chinook Therapeutics' major shareholders?

Chinook Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.94%), State Street Corp (4.05%), Alpine Associates Management Inc. (3.18%), Eventide Asset Management LLC (2.68%), Suvretta Capital Management LLC (2.43%) and Dimensional Fund Advisors LP (1.99%). Insiders that own company stock include Alan Glicklich, Andrew James King, Davis Jerel, Eric Bjerkholt, Eric Dobmeier, Mahesh Krishnan, Srinivas Akkaraju, Tom Frohlich, Versant Venture Capital Vii, L and William Mariner Greenman.
View institutional ownership trends.

What is Chinook Therapeutics' stock price today?

One share of KDNY stock can currently be purchased for approximately $40.39.

How much money does Chinook Therapeutics make?

Chinook Therapeutics (NASDAQ:KDNY) has a market capitalization of $2.90 billion and generates $6.13 million in revenue each year. The company earns $-187,870,000.00 in net income (profit) each year or ($3.52) on an earnings per share basis.

How many employees does Chinook Therapeutics have?

The company employs 214 workers across the globe.

How can I contact Chinook Therapeutics?

Chinook Therapeutics' mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The official website for the company is chinooktx.com. The company can be reached via phone at (206) 485-7241 or via email at investors@aduro.com.

This page (NASDAQ:KDNY) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -